Skip to content

Cart

Your cart is empty

S23 Powder, 1gr

Sale price€54,99

S23
S23 Powder, 1gr Sale price€54,99

S23

S23 is an orally available, selective androgen receptor modulator (SARM). This agent was originally developed by GTX Inc. as a male form of hormonal contraception. It has a high affinity for the androgen receptor, with a Ki value of 1.7 nM. A study published by Jones et al. compared the effectiveness of S23 in both castrated and intact male rats.

Effects of S23 on Fertility

In castrated male rats, the effective dose of S23 was 0.43 mg/day in the prostate and 0.079 mg/day in the levator ani muscle. In intact male rats, a dose higher than 0.1 mg/day resulted in a suppression of luteinizing hormone (LH) by more than 50%. This dose was consistent with a reduction in prostate size and an increase in the size of the levator ani muscle.

In a study with intact male subjects treated with both S23 and estradiol benzoate (to maintain sexual behavior), no sperm was found in the testicles in four of six subjects after 10 weeks. In addition, no pregnancy was reported in any of the six laboratory animals. After treatment, the infertility was completely reversible; all subsequent mating trials resulted in pregnancy.

Effects of S23 on Muscle Mass and Body Fat

S23 shows effects on muscle mass and body fat similar to those of anabolic steroids. Studies in male rats showed that treatment with S23 led to a decrease in total body weight and fat mass. The rats in this study were also administered estradiol benzoate to maintain sexual behavior. Despite the known muscle loss due to estrogens, the combination with S23 neutralized this effect and resulted in an increase in muscle mass in the male rats.

In addition, another study showed that S23 may be effective against muscle loss caused by long-term use of glucocorticoids. This study also looked at the effects of S23 on muscle atrophy caused by castration. Muscle loss was noted in both scenarios, but the administration of S23 and testosterone blocked the dexamethasone-induced dephosphorylation of Akt. The results suggest that S23 may be an effective treatment against glucocorticoid-induced muscle loss.

DISCLAIMER
This material is sold for use in laboratory research only. Terms of sale apply. Not for human consumption, nor for medical, veterinary or household use. Familiarize yourself with our DISCLAIMER before ordering.

 

S23 – solution, 600mg (20mg/mL)

Application

Selective Androgen Receptor Modulator

CAS

1010396-29-8

molar massa

416.753 g/mol

 Chemical formula

C18H13ClF4N2O3

IUPAC name

{4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]-2-methylphenoxy}acetic acid

Synonyms

UNII-XDK89456WM, 3-(4-cyanophenoxy)-N-(4-cyano-3-trifluoromethylphenyl)-2-hydroxy-2-methylpropionamide, CCTH-methylpropionamide

Bulletin

room temperature

Solubility

Soluble in ethanol, PEG400, PPG

Organoleptic profile


Physical form

Powder

Specification


Terms and conditions

This material is sold for use in laboratory research only. Terms of sale apply. Not for human consumption, nor for medical, veterinary or household use. Please familiarize yourself with our DISCLAIMER before ordering.